The question
How should a global renal-care business create a credible five-year growth path in a market where the core category is established, customer economics vary materially, and adjacent technologies create additional pools of opportunity?
My role
I led the strategy workstream, bringing together market sizing, segment prioritisation, customer economics, portfolio choices and commercial implications into a multi-year growth agenda.
What mattered
The work focused on four questions:
-
Where was underlying market growth concentrated, and how much of that growth was realistically addressable?
-
Which product, customer and channel segments warranted disproportionate focus?
-
Which adjacent opportunities could reinforce the core business rather than dilute management attention?
-
What commercial capabilities would be required to translate market potential into revenue?
A key part of the work was distinguishing between theoretical market opportunity and realistically capturable growth. Market size alone was insufficient; customer economics, clinical adoption, channel access, account prioritisation and organisational capability materially influenced the achievable growth path.
The broader lesson
Healthcare growth strategies become more useful when the market model and the execution model are built together.
A large theoretical opportunity is not the same as a reachable one. The more important question is how much of that opportunity can be converted into revenue given customer economics, clinical adoption, access, commercial capability and management focus.